

RESEARCH ARTICLE

# Thermal solvent-free synthesis of chromonyl chalcones, pyrazolines and their *in vitro* antibacterial, antifungal activities

Zeba N. Siddiqui<sup>1</sup>, Shagufta Praveen<sup>1</sup>, Mohammed Musthafa. T.N<sup>1</sup>, Anis Ahmad<sup>2</sup>, and Asad U. Khan<sup>2</sup>

<sup>1</sup>Department of Chemistry, Aligarh Muslim University, Aligarh, India and <sup>2</sup>Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India

## Abstract

A facile and ecofriendly synthesis of new chromonyl chalcones **3a-b** from 3-formylchromone **1** and active methyl compounds **2a-b** is reported under thermal solvent-free heating condition in good yields. The chromonyl chalcones **3a-b** were used as intermediates under green condition for the synthesis of new bioactive pyrazoline derivatives **4a-f**. The compounds were tested for antimicrobial activity by disk diffusion assay with slight modifications against Gram-positive, Gram-negative strains of bacteria as well as fungal strains. The investigation of antimicrobial screening revealed that compounds **3a-b** and **4a-f** showed antibacterial and antifungal activities.

**Keywords:** 3-Formylchromone, green synthesis, antimicrobial activity

## Introduction

Human infections particularly those involving microorganisms like bacteria and fungi cause serious damages in tropical and subtropical countries of the world and these infections are a major threat to public health despite tremendous growth in human chemotherapeutic medicine. These infections can occur in invasive form, and are an increasing problem due to the increase of their incidence in hospitals, especially in patients who are undergoing cancer treatment, transplantation or are immune suppressed for other reasons<sup>1</sup>. Methicillin-resistant *Staphylococcus aureus* (MRSA) is common Gram-positive pathogen of nosocomial infections which account for outbreaks and are increasing in frequency<sup>2,3</sup>. *Escherichia coli* is responsible for the world's most common and serious infectious diseases like invasive dysentery and diarrhea<sup>4,5</sup>. The different parasitic bacteria such as *S. aureus*, *S. pyogenes*, *S. typhimurium*, *E. coli* have important effect on the human's mucosal health. The infection with these microorganisms may have

significant impact on huge demolition of host tissues and severe diseases<sup>6,7</sup>. Thus, antibiotics provide the main basis for the therapy of microbial (bacterial and fungal) infections. However, overuse of antibiotics has become the major factor for the emergence and dissemination of multi-drug resistant strains of several groups of microorganisms<sup>8</sup>. Furthermore, the drugs available are either too expensive or have undesirable side effects or contraindications<sup>9</sup>. The aim of this work is the synthesis of new molecules able to inhibit the growth of Gram-positive, Gram-negative bacteria and fungi.

Chromones comprise a vast array of oxygen containing compounds ubiquitous in plants<sup>10</sup>. They form basic nucleus of flavones and have been recognized as the essential component of pharmacophores of a large number of bioactive molecules<sup>11</sup>. Interest in chromone containing structures stems from their widespread occurrence in molecules that exhibit significant antimicrobial<sup>12</sup>, antioxidant<sup>13</sup>, neuroprotective<sup>14</sup>, HIV-inhibitory<sup>15</sup> and anticancer<sup>16</sup> activities. In addition, chromone derivatives

Address for Correspondence: Zeba N. Siddiqui, Department of Chemistry, Aligarh Muslim University, Aligarh 202 002, India.  
E-mail: siddiqui\_zeba@yahoo.co.in

(Received 11 December 2010; revised 28 March 2011; accepted 29 March 2011)

are also active at benzodiazepine receptors, lipoxigenases and cyclooxygenases<sup>17</sup>. Chalcones and pyrazolines are another important class of compounds with wide spread biological applications<sup>18,19</sup>.

Growing concern about environmental damage leads to an urgent requirement for the development of efficient and environmentally benign chemical processes for the synthesis of new molecules. Solvent-free reactions are gaining importance in this context as the procedure demonstrates obvious and significant advantages<sup>20</sup>. However, most of the reported solvent-free accomplishments focus on reactions promoted by microwave irradiation, hand grinding and mechanical milling<sup>21–23</sup>. In contrast, reports on direct heating of the reagents under thermal heating conditions without any solvent are relatively less explored. To the best of our knowledge, no reports have been so far made in the synthesis of chromonyl chalcones and derivatives in solvent-free thermal heating condition. Thus, in the present study, we wish to report the novel synthesis of series of chromonyl chalcones and pyrazolines in excellent yields, under thermal solvent-free heating condition and their evaluation for antimicrobial activities.

## Materials and methods

### Chemistry

Melting points were taken in Riechert Thermover (Austria) instrument and are uncorrected. The IR spectra were recorded on Perkin Elmer (Spectro Lab, United Kingdom) RXI spectrometer in KBr, <sup>1</sup>H NMR on Bruker DRX 300 MHz spectrometer and Bruker Avance (Switzerland) II 400 MHz spectrometer using tetramethyl silane as the internal standard and DMSO-d<sub>6</sub>/CDCl<sub>3</sub> as solvent. Mass spectra were obtained on Jeol-SX-102 (FAB) spectrometer. The microanalytical data were collected on Carlo Erba (Carlo Erba Instruments, Germany) analyzer model 1108. 3-Formylchromone **1**<sup>24</sup>, hydrazinobenzothiazole<sup>25</sup> and 5-acetylbarbituric acid **2b**<sup>26</sup> were synthesized by reported methods. Dehydroacetic acid **2a** was purchased from E. Merck (Merck, Darmstadt, Germany). Other chemicals were of commercial grade and used without further purification. The purity of the compounds was checked by thin layer chromatography (TLC) on glass plates coated with silica gel G<sub>254</sub> (E. Merck) using chloroform-methanol (3:1 v/v) mixture as mobile phase and visualized by iodine vapours.

### General procedure for the synthesis of chalcones (3a-b) under conventional method

To a solution of 3-formylchromone **1** (1.00 g, 5.7 mmol) and dehydroacetic acid **2a** (0.965 g, 5.7 mmol)/5-acetyl barbituric acid **2b** (0.970 g, 5.7 mmol) in methanol (12 mL), pyridine (0.5 mL) was added. The reaction mixture was stirred at room temperature/refluxed for a specified time. After completion of the reaction (checked by TLC), the reaction mixture was concentrated and cooled at room temperature. The yellow solid, which precipitated out, was filtered, washed with methanol and dried. The compounds were

purified by recrystallization from chloroform-methanol (1:3 v/v) mixture as shining yellow crystals.

### General procedure for the synthesis of chalcones (3a-b) under solvent-free condition

A mixture of 3-formylchromone **1** (1.00 g, 5.7 mmol), dehydroacetic acid **2a** (0.965 g, 5.7 mmol)/ 5-acetyl barbituric acid **2b** (0.970 g, 5.7 mmol) and pyridine (0.3 mL) were mixed well and air dried. The reaction mixture was then heated at 80 °C in a 100 mL beaker. After completion of the reaction (checked by TLC), the reaction mixture was slurred in water (25 mL). The yellow solid obtained was filtered, washed with methanol and dried. The compounds were purified by recrystallization from chloroform-methanol (1:3 v/v) mixture as shining yellow crystals.

### (2E)-1-(4-Hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-3-(4-oxo-4H-1-benzopyran-3-yl)-2-propen-1-one (3a)

Pale yellow crystals; mp 235–237°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ: 2.28 (3H, s, CH<sub>3</sub>), 5.96 (1H, s, C-5'), 7.36–7.73 (3H, m, Ar-H), 7.87 (1H, d, *J* = 15.9 Hz, Ha), 8.32 (1H, s, C-2), 8.35 (1H, dd, *J* = 7.8 Hz, 1.8 Hz, C-5), 8.77 (1H, d, *J* = 15.9 Hz, Hb). IR (KBr) ν: 3437 (OH), 1721 (C=O), 1659 (C=O). MS-FAB *m/z* (%): 324 (M<sup>+</sup>, 100), 323 (25), 309 (5), 308 (10), 279 (10), 198 (80), 171 (70), 120 (10), 92 (5). Anal. Calcd for C<sub>18</sub>H<sub>12</sub>O<sub>6</sub>: C, 66.67; H, 3.73. Found: C, 66.53; H, 3.69.

### (2E)-3-(4-Oxo-4H-1-benzopyran-3-yl)-1-(2,4,6-pyrimidinetrione-5-yl)-2-propen-1-one (3b)

Light yellow crystals; mp >300°C. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ: 7.40 (1H, d, *J* = 15.2 Hz, Ha), 7.55–7.91 (3H, m, Ar-H), 8.17 (1H, dd, *J* = 8.0 Hz, 1.6 Hz, C-5), 8.95 (1H, s, C-2), 9.09 (1H, d, *J* = 15.9 Hz, Hb), 11.06 (1H, s, NH), 11.76 (1H, s, NH). IR (KBr) ν: 3078 (NH), 1740 (C=O), 1643 (C=O). MS-FAB *m/z* (%): 326 (M<sup>+</sup>, 60), 206 (10), 198 (70), 171 (65), 145 (50), 120 (40). Anal. Calcd for C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>6</sub>: C, 58.83; H, 3.06; N, 8.58. Found: C, 58.72; H, 3.14; N, 8.44.

### General procedure for the synthesis of pyrazolines (4a-e) and bipyrazole (4f) under conventional method

The compound **3a-b** (1.00 g, 3 mmol) was dissolved in acetic acid (8 mL) and hydrazines (hydrazine hydrate (0.15 g, 3 mmol)/hydrazinobenzothiazole (0.49 g, 3 mmol)/phenylhydrazine (0.51 g, 3 mmol) added to it. The reaction mixture was stirred at room temperature or refluxed in a heating mantle for specified period of time. After that, the reaction mixture was cooled and poured into ice-cold water (20 mL). The solid, which precipitated out, was filtered, washed with water and dried. Purification of **4a-f** was achieved by recrystallization from chloroform-methanol (1:4 v/v) mixture.

### General procedure for the synthesis of pyrazolines (4a-e) and bipyrazole (4f) under solvent-free heating method

The compound **3a-b** (1.00 g, 3 mmol) and hydrazines (hydrazine hydrate (0.15 g, 3 mmol)/

hydrazinobenzothiazole (0.49 g, 3 mmol)/phenylhydrazine (0.51 g, 3 mmol) were mixed well and heated at 80°C in a 100 mL beaker. After completion of the reaction (checked by TLC), the reaction mixture was slurred in water (20 mL). The solid, obtained was filtered, washed with methanol and dried. The compounds were purified by recrystallization from chloroform-methanol (1:4 v/v) mixture to get **4a-f**.

### 3-(4-Hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-5-(4-oxo-4H-1-benzopyran-3-yl)pyrazoline (**4a**)

White solid; mp 260–262°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ: 2.27 (3H, s, CH<sub>3</sub>), 3.69–3.92 (2H, m, He, Hf), 5.20–5.26 (1H, m, Hd), 6.04 (1H, s, C-5'), 6.68 (1H, s, NH), 7.35–7.68 (3H, m, Ar-H), 8.02 (1H, s, C-2), 8.16 (1H, d, J=7.9 Hz, C-5), 12.78 (1H, s, OH, D<sub>2</sub>O exchangeable). IR (KBr) ν: 1700 (C=O), 1665 (C=O). MS-FAB *m/z* (%): 338 (M<sup>+</sup>, 60), 337 (70), 309 (5), 281 (5), 217 (5), 193 (15), 189 (5), 185 (5), 163 (10), 120 (15), 93 (45), 92 (10). Anal. Calcd for C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>O<sub>5</sub>: C, 63.90; H, 4.17; N, 8.28. Found: C, 63.83; H, 4.24; N, 8.22.

### 1-Benzothiazolyl-3-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-5-(4-oxo-4H-1-benzopyran-3-yl)pyrazoline (**4b**)

Pale yellow solid; mp >300°C. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ: 2.48 (3H, s, CH<sub>3</sub>), 3.07–4.14 (2H, m, He, Hf), 5.44–5.50 (1H, m, Hd), 6.29 (1H, s, C-5'), 8.02 (1H, d, J=7.1 Hz, C-5), 7.05–7.81 (7H, m, Ar-H), 8.41 (1H, s, C-2) 12.23 (1H, s, OH, D<sub>2</sub>O exchangeable). IR (KBr) ν: 1727 (C=O), 1649 (C=O). MS-FAB *m/z* (%): 471 (M<sup>+</sup>, 100), 443 (5), 415 (5), 428 (5), 322 (5), 307 (50), 177 (5), 120 (20). Anal. Calcd for C<sub>25</sub>H<sub>17</sub>N<sub>3</sub>O<sub>5</sub>S: C, 63.68; H, 3.63; N, 8.91. Found: C, 63.61; H, 3.67; N, 8.87.

### 5-(4-Oxo-4H-1-benzopyran-3-yl)-3-(2,4,6-pyrimidinetrione-5-yl)pyrazoline (**4c**)

White solid; mp >300°C. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ: 3.43–3.49 (1H, m, He), 3.82–3.89 (1H, m, Hf), 4.69–4.75 (1H, m, Hd), 7.49–7.84 (3H, m, Ar-H), 6.69 (1H, s, NH), 8.09 (1H, dd, J=8.0 Hz, 1.2 Hz, C-5), 8.29 (1H, s, C-2), 10.31 (1H, s, NH), 10.45 (1H, s, NH). IR (KBr) ν: 3214 (NH), 3069 (NH), 1721 (C=O), 1628 (C=O). MS-FAB *m/z* (%): 340 (M<sup>+</sup>, 75), 326 (25), 322 (30), 206 (5), 198 (5), 171 (30), 145 (5), 120 (30). Anal. Calcd for C<sub>16</sub>H<sub>12</sub>N<sub>4</sub>O<sub>5</sub>: C, 56.47; H, 3.52; N, 16.47. Found: C, 56.31; H, 3.46; N, 16.54.

### 1-Phenyl-5-(4-oxo-4H-1-benzopyran-3-yl)-3-(2,4,6-pyrimidinetrione-5-yl)pyrazoline (**4d**)

Pale yellow solid; mp >300°C. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ: 3.51–3.56 (1H, m, He), 3.73–3.78 (1H, m, Hf), 4.42–4.44 (1H, m, Hd), 7.25–7.45 (8H, m, Ar-H), 7.55 (1H, s, C-2), 7.79 (1H, dd, J=7.6 Hz, 1.8 Hz, C-5), 10.60 (1H, s, NH), 10.76 (1H, s, NH). IR (KBr) ν: 3068 (NH), 1737 (C=O), 1649 (C=O). MS-FAB *m/z* (%): 416 (M<sup>+</sup>, 70), 415(5), 326 (45), 198 (40) 171 (30), 120 (20). Anal. Calcd for C<sub>22</sub>H<sub>16</sub>N<sub>4</sub>O<sub>5</sub>: C, 63.46; H, 3.84; N, 13.46. Found: C, 63.50; H, 3.71; N, 13.38.

### 1-Benzothiazolyl-5-(4-oxo-4H-1-benzopyran-3-yl)-3-(2,4,6-pyrimidinetrione-5-yl)pyrazoline (**4e**)

Brown crystals; mp >300°C. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ: 3.81–3.87 (1H, m, He), 4.10–4.17 (1H, m, Hf), 5.49–5.53 (1H, m, Hd), 7.12–7.76 (7H, m, Ar-H), 8.15 (1H, dd, J=8.0 Hz, 1.6 Hz, C-5), 8.27 (1H, s, C-2), 11.17 (1H, s, NH), 11.56 (1H, s, NH). IR (KBr) ν: 3069 (NH), 1701 (C=O), 1644 (C=O). MS-FAB *m/z* (%): 473 (M<sup>+</sup>, 50), 326 (20), 198 (10), 145 (20), 120 (30). Anal. Calcd for C<sub>23</sub>H<sub>15</sub>N<sub>5</sub>O<sub>5</sub>S: C, 58.35; H, 3.17; N, 14.79. Found: C, 58.27; H, 3.25; N, 14.71.

### 1-Phenyl-3-[4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl]-5-[5-(2-hydroxyphenyl)-1-phenyl pyrazol-4-yl]pyrazoline (**4f**)

Red crystals; mp 250–253°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ: 2.35 (3H, s, CH<sub>3</sub>), 3.38–3.50 (1H, m, He), 3.66–4.11 (1H, m, Hf), 4.99–5.34 (1H, m, Hd), 6.01 (1H, s, C-5'), 6.90–7.13 (4H, m, Ar-H), 7.18–7.42 (14H, m, Ar-H), 7.68 (1H, s, Hc), 13.27 (1H, s, OH, D<sub>2</sub>O exchangeable). IR (KBr) ν: 3432 (OH), 1701 (C=O). MS-FAB *m/z* (%): 504 (M<sup>+</sup>, 70), 476 (5), 460 (15), 449 (8), 445 (10), 379 (5), 352 (20), 279 (15). Anal. Calcd for C<sub>30</sub>H<sub>24</sub>N<sub>4</sub>O<sub>4</sub>: C, 71.41; H, 4.79; N, 11.10. Found: C, 71.26; H, 4.84; N, 11.06.

### Antibacterial studies

The newly synthesized compounds were screened for their antibacterial activity against *Streptococcus pyogenes* (clinical isolate), MRSA (+ve), *Pseudomonas aeruginosa* (ATCC-27853), *Klebsiella pneumoniae* (clinical isolate) and *E. coli* (ATCC-25922) bacterial strains by disk diffusion method<sup>27,28</sup>. A standard inoculums (1–2 × 10<sup>7</sup> c.f.u./mL 0.5 McFarland standards) was introduced on to the surface of sterile agar plates, and a sterile glass spreader was used for even distribution of the inoculums. The disks measuring 6 mm in diameter were prepared from Whatman no. 1 filter paper and sterilized by dry heat at 140°C for 1 h. The sterile disks previously soaked in a known concentration of the test compounds were placed in nutrient agar medium. Solvent and growth controls were kept. Ciprofloxacin (30 µg) was used as positive control while the disk poured in DMSO was used as negative control. The plates were inverted and incubated for 24 h at 37°C. The susceptibility was assessed on the basis of diameter of zone of inhibition against Gram-positive and Gram-negative strains of bacteria. Inhibition zones were measured and compared with the controls. The bacterial zones of inhibition values are given in Table 1.

Minimum inhibitory concentrations (MICs) were determined by broth dilution technique. The nutrient broth, which contained logarithmic serially two fold diluted amount of test compound and controls were inoculated with approximately 5 × 10<sup>5</sup> c.f.u./mL of actively dividing bacteria cells. The cultures were incubated for 24 h at 37°C and the growth was monitored visually and spectrophotometrically. The lowest concentration (highest dilution) required to arrest the growth of bacteria was regarded as MIC. To obtain the minimum bactericidal concentration (MBC), 0.1 mL volume was taken from

Table 1. Antibacterial activity of compounds **3a-4f**.

Compounds	Gram-positive bacteria						Gram-negative bacteria					
	<i>Staphylococcus pyogenes</i>			MRSA*			<i>Pseudomonas aeruginosa</i>			<i>Klebsiella pneumoniae</i>		
	Zone	MIC	MBC	Zone	MIC	MBC	Zone	MIC	MBC	Zone	MIC	MBC
<b>3a</b>	13.5±0.4	25	100	13.4±0.4	25	50	15.1±0.6	50	100	12.6±0.2	25	50
<b>3b</b>	11.4±0.5	25	50	11.1±0.5	50	100	13.2±0.4	25	50	10.7±0.5	50	100
<b>4a</b>	21.5±0.2	25	100	20.6±0.4	50	100	26.3±0.6	50	100	21.5±0.2	50	>100
<b>4b</b>	20.3±0.4	25	100	19.8±0.3	50	100	22.4±0.2	50	>100	18.4±0.5	50	>100
<b>4c</b>	18.1±0.5	25	100	17.3±0.4	25	>100	20.1±0.4	100	>100	16.1±0.5	50	>100
<b>4d</b>	15.2±0.4	50	100	14.5±0.2	50	100	12.2±0.3	50	>100	14.5±0.4	100	>100
<b>4e</b>	10.4±0.4	50	100	10.1±0.3	50	>100	12.2±0.2	50	>100	10.5±0.3	50	>100
<b>4f</b>	15.2±0.2	50	100	10.7±0.4	50	100	15.2±0.3	50	100	13.3±0.2	50	>100
Standard	23.0±0.2	12.5	12.5	22.0±0.2	6.25	12.5	32.0±0.3	12.5	25	19.0±0.2	6.25	25
DMSO	—	—	—	—	—	—	—	—	—	—	—	—

Diameter of zone of inhibition (mm), MIC and MBC results of compounds **3a-4f** and positive control griseofulvin. Positive control (Standard); ciprofloxacin and negative control (DMSO) measured by the Halo Zone Test (unit, mm). \*Methicillin resistant *S. aureus* (MRSA +ve). MIC (µg/mL), minimum inhibitory concentration, i.e., the lowest concentration of the compound to inhibit the growth of bacteria completely; MBC (µg/mL), minimum bactericidal concentration, i.e., the lowest concentration of the compound for killing the bacteria completely.



each tube and spread on agar plates. The number of c.f.u. was counted after 18–24 h of incubation at 35°C. MBC was defined as the lowest drug concentration at which 99.9% of the inoculums were killed. The minimum inhibitory concentration and minimum bactericidal concentration are given in Table 1.

### Antifungal studies

Antifungal activity was also done by disk diffusion method. For assaying antifungal activity *Candida albicans*, *Aspergillus fumigatus*, *Trichophyton mentagrophytes* and *Penicillium marneffeii* were recultured in DMSO by agar diffusion method<sup>29,30</sup>. Sabourauds agar media was prepared by dissolving peptone (1 g), D-glucose (4 g) and agar (2 g) in distilled water (100 mL) and adjusting pH to 5.7. Normal saline was used to make a suspension of spore of fungal strain for lawning. A loopful of particular fungal strain was transferred to 3 mL saline to get a suspension of corresponding species. 20 mL of agar media was poured into each Petri dish. Excess of suspension was decanted and the plates were dried by placing in an incubator at 37°C for 1 h. Using an agar punch, wells were made and each well was labeled. A control was also prepared in triplicate and maintained at 37°C for 3–4 days. The fungal activity of each compound was compared with griseofulvin as standard drug. Inhibition zones were measured and compared with the controls. The fungal zones of inhibition values are given in Table 2. The nutrient broth, which contained logarithmic serially two fold diluted amount of test compound and controls was inoculated with approximately  $1.6 \times 10^4$ – $6 \times 10^4$  c.f.u./mL. The cultures were incubated for 48 h at 35°C and the growth was monitored. The lowest concentration (highest dilution) required to arrest the growth of fungi was regarded as MIC. To obtain the minimum fungicidal concentration (MFC), 0.1 mL volume was taken from each tube and spread on agar plates. The number of c.f.u. was counted after 48 h of incubation at 35°C. MFC was defined as the lowest drug concentration at which 99.9% of the inoculums were killed. The MIC and MFC are given in Table 2.

## Results and discussion

### Chemistry

3-Formylchromone has emerged as an important starting material for incorporation of chromone moiety, ever since its convenient synthesis was reported in 1970s<sup>24</sup>. It has been used as an important synthon due to the presence of three electron deficient centers *viz* C-2, C-4 carbonyl and C-3 formyl groups. In the present study, we carried out the reaction of 3-formylchromone **1** and active methyl compounds *viz* dehydroacetic acid **2a** and 5-acetyl barbituric acid **2b** under different reaction conditions. Initially reactions were conducted at room temperature in the presence of basic catalyst pyridine. The reactions afforded the expected chromonyl chalcones **3a–b** in 18–25 hours with 62–70% yields (Scheme 1). The reactions carried using methanol as a solvent under conventional heating condition were found to be completed in 10–16 h, but there was no substantial increase in yields of products. This prompted us to carry out reactions under solvent-free heating technique by simply heating the starting materials with the catalyst. To our pleasant surprise, the reactions were completed in short span of time (12–15 min) with considerable increase in yields (88–92%) and were devoid of any toxic waste products. Thus, the present protocol explains the superiority of thermal solvent-free reactions over the conventional methods. The products obtained were characterized by elemental and spectral (IR, <sup>1</sup>H NMR and mass spectrometry) analysis.

The <sup>1</sup>H NMR spectrum of the compound **3b** showed *trans* olefinic protons Ha and Hb as *ortho* coupled doublets at  $\delta$  7.40 ( $J$  = 15.2 Hz) and 9.09 ( $J$  = 15.9 Hz), respectively. The value of spin-spin coupling constant  $J_{ab}$ , in the range of 15–16 Hz, is indicative of the *E*-configuration of chalcone. The three aromatic protons of chromone moiety were discernible in the form of multiplet at  $\delta$  7.55–7.91 whereas C-2 and C-5 protons appeared as a singlet and doublet of doublet at  $\delta$  8.95 and 8.17 respectively. The NH protons of barbituric acid moiety appeared as two broad singlets at  $\delta$  11.06 and 11.76.


Table 2. Antifungal activity of compounds **3a–4f**.

Compounds	<i>Candida albicans</i>			<i>Aspergillus fumigatus</i>			<i>Trichophyton mentagrophytes</i>			<i>Penicillium marneffeii</i>		
	Zone	MIC	MFC	Zone	MIC	MFC	Zone	MIC	MFC	Zone	MIC	MFC
3a	22.2 ± 0.4	12.5	50	19.7 ± 0.3	12.5	50	15.8 ± 0.9	25	100	14.3 ± 0.2	25	50
3b	21.3 ± 0.3	12.5	25	19.6 ± 0.4	25	100	15.4 ± 0.2	12.5	50	12.9 ± 0.3	25	50
4a	20.1 ± 0.3	25	100	18.1 ± 0.2	25	100	14.3 ± 0.3	25	100	11.7 ± 0.2	50	100
4b	20.1 ± 0.3	25	100	17.2 ± 0.5	50	100	13.7 ± 0.4	50	100	10.1 ± 0.4	50	100
4c	19.8 ± 0.5	50	100	17.6 ± 0.6	50	100	12.1 ± 0.3	50	100	10.3 ± 0.6	25	100
4d	18.1 ± 0.3	25	100	16.5 ± 0.4	25	100	11.7 ± 0.5	50	100	9.2 ± 0.4	50	100
4e	17.9 ± 0.3	50	100	15.5 ± 0.5	50	>100	10.4 ± 0.2	50	>100	8.9 ± 0.3	50	100
4f	19.4 ± 0.5	50	100	17.1 ± 0.6	100	>100	12.1 ± 0.4	50	100	10.3 ± 0.6	50	>100
Standard	30.0 ± 0.2	6.25	25	27.0 ± 0.2	12.5	12.5	24.0 ± 0.3	6.25	25	20.0 ± 0.5	12.5	25
DMSO	–	–	–	–	–	–	–	–	–	–	–	–

Diameter of zone of inhibition (mm), MIC and MFC results of compounds **3a–4f** and positive control griseofulvin. Positive control (griseofulvin) and negative control (DMSO) measured by the Halo Zone Test (Unit, mm). MIC ( $\mu$ g/mL), minimum inhibitory concentration, i.e., the lowest concentration of the compound to inhibit the growth of fungi completely; MFC ( $\mu$ g/mL), minimum fungicidal concentration, i.e., the lowest concentration of the compound for killing the fungi completely.

Nitrogen bases such as hydrazines react with  $\alpha,\beta$ -unsaturated carbonyl compounds to give pyrazolines<sup>31</sup>. With the objective of synthesizing pyrazolines containing chromone moiety, chromonyl chalcones **3a-b** were allowed to react with different hydrazines in conventional method using acetic acid as solvent and under solvent-free heating conditions. As expected, pyrazolines **4a-e** were obtained from hydrazine hydrate, hydrazinobenzothiazole and phenylhydrazine (Scheme 1) and the

results were comparable with reactions performed under conventional procedures. However, in case of reaction of **3a** with phenylhydrazine, the mixture did not afford the desired pyrazoline, instead a bipyrazole **4f** was obtained due to the ring opening reaction of pyrone ring both under conventional and thermal solvent-free methods. All the newly synthesized compounds were characterized by elemental and spectral (IR, <sup>1</sup>H NMR and mass spectrometry) analysis.



Scheme 1. Formation of chalcones **3a-b** and their reaction with different hydrazines to give compounds **4a-f**.

The  $^1\text{H}$  NMR spectrum of compound **4f** indicated the absence of resonances attributable to C-2 olefinic and C-5 protons of chromone moiety, whereas compound **4a/4b** showed these diagnostic signals of C-2 proton as singlet at  $\delta$  8.02, 8.41 and C-5 proton as doublet at  $\delta$  8.16, 8.02 respectively. These observations suggest the opening of pyrone ring under the action of phenylhydrazine to lead the formation of bipyrazole **4f**. The other prominent peaks as obtained are explained in the experimental part.

### Pharmacology

The investigation of antibacterial screening data revealed that all the tested compounds **3a-4f** showed moderate to good bacterial inhibition. Among the tested bacterial strains, good inhibitory results were obtained against *S. pyogenes* and *E. coli*. The structural activity study showed that chalcones **3a, 3b** and their derivatives **4a-f** have varying degrees of microbial inhibition. The antimicrobial activity seemed to be dependent on the nature of heterocyclic moieties. A comparative study (Table 1) also revealed that chromonyl chalcones **3a-b**, are more potent antibacterial agents than chromonyl pyrazolines **4a-f**. Compounds **3a, 3b, 4a, 4b** and **4c** showed good inhibition ( $\text{MIC} = 25 \mu\text{g/mL}$ ) against *S. pyogenes*. The maximum inhibition was observed in **3a** and **4c** against *S. aureus* (MRSA +ve). Except **3a** and **3b** all other compounds showed moderate to less activity results against *P. aeruginosa*, *K. pneumoniae* and *E. coli* bacterial strains. The MICs i.e., the lowest concentration of the compounds to inhibit the growth of bacteria completely were in the range of 25–100  $\mu\text{g/mL}$ . The minimum bactericidal concentrations (MBCs) i.e., the lowest concentration of the compounds for killing the bacteria completely were found to be two, three or four folds higher than the corresponding MIC results.

The antifungal screening data of the compounds also revealed good to moderate activity. Among the tested fungal strains, good inhibitory results were obtained against *C. albicans*, and *A. fumigatus*. Again the comparative study (Table 2) revealed that chromonyl chalcones **3a-b**, were found to have better inhibitory action than pyrazolines **4a-f**. The compounds **3a, 3b, 4a, 4b** and **4d** showed effective inhibition results ( $\text{MIC} = 12.5\text{--}25 \mu\text{g/mL}$ ) against *C. albicans*. The maximum inhibition was observed in **3a, 3b** and **4a** against *A. fumigatus*, and *T. mentagrophytes* fungal cultures. The inhibitory activity against *P. marneffei* was significantly higher for the compounds **3a, 3b** and **4c** than the other tested compounds. Compounds **4c-f** were moderately active against most of the fungal strains. The MICs, i.e., the lowest concentration of the compounds to inhibit the growth of fungi completely were in the range of 12.5–100  $\mu\text{g/mL}$ . The MFCs, i.e., the lowest concentration of the compounds for killing the fungi completely were found to be two, three or four folds higher than the corresponding MIC results.

Considering the results obtained from antifungal and antibacterial tests together, it is noteworthy to mention that tested compounds are more active towards fungi

than bacteria. Thus, the nature of heterocycles and basic skeleton of molecule have significant influence on the extent of antibacterial and antifungal activities. A comparative study of the activity results (Tables 1 and 2) with standard drugs (ciprofloxacin, griseofulvin) revealed that none of the compound exceeds the activity of commercial drugs. However, compounds have produced the marked enhancement in the potency of these analogues as antibacterial and antifungal agents.

Molecular targets of the synthesized compounds on the bacteria and fungi were identified using BioSpec Module of Raasi Suite. Every molecule has multiple targets on bacteria and fungi. The synthesized molecules have the following molecular targets: ATP-binding cassette, sub-family C, member 1 isoform 1 inhibitor, Pyruvate kinase, muscle isoform M2 activator, Eukaryotic translation initiation factor 4 $\gamma$ , 1 isoform 4 inhibitor.

### Conclusions

In summary, a clean and convenient synthesis of novel chromone derivatives has been developed. The procedure offers several advantages including mild reaction conditions as well as simple experimental and product isolation procedures, thus, making the current “green protocol” as a useful and attractive methodology for the synthesis of series of novel heterocycles in excellent yields from cheap and readily available starting materials. The antibacterial, antifungal screening data revealed that newly generated compounds are good antimicrobial agents. The newly generated compounds can be used as template for future development through modification and derivatization to design more potent and selective antimicrobial agents.

### Acknowledgments

The authors are thankful to University Grants Commission, New Delhi for providing financial assistance in the form of major research project [F.No. 37-15/2009 (SR)], SAIF, CDRI, Lucknow, India for providing analytical, spectral data and Mr Sameer Chaudhary, MD RASA Life Science Informatics, Pune, India for providing drug target identification using BioSpec Module of Raasi Suite.

### Declaration of Interest

The authors have declared no conflicts of Interest.

### References

- Oliveira RDR, Maffei CML, Martinez R. Infecção urinária hospitalar por leveduras do gênero Candida. Rev Assoc Med Bras 2001;47:231–235.
- Diekema DJ, BootsMiller BJ, Vaughn TE, Woolson RF, Yankey JW, Ernst EJ et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004;38:78–85.
- Georgopapadakou NH. Infectious disease 2001: drug resistance, new drugs. Drug Resist Updat 2002;5:181–191.

4. Zhang W, Berberov EM, Freeling J, He D, Moxley RA, Francis DH. Significance of heat-stable and heat-labile enterotoxins in porcine colibacillosis in an additive model for pathogenicity studies. *Infect Immun* 2006;74:3107–3114.
5. Shaheen HI, Khalil SB, Rao MR, Abu Elyazeed R, Wierzbza TF, Peruski LF Jr et al. Phenotypic profiles of enterotoxigenic *Escherichia coli* associated with early childhood diarrhea in rural Egypt. *J Clin Microbiol* 2004;42:5588–5595.
6. Puerto AS, Fernández JG, del Castillo Jde D, Pino MJ, Angulo GP. *In vitro* activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of *Escherichia coli*. *Diagn Microbiol Infect Dis* 2006;54:135–139.
7. Nolan CM, Chalhoub EG, Nash DG, Yamauchi T. Treatment of bacterial meningitis with intravenous amoxicillin. *Antimicrob Agents Chemother* 1979;16:171–175.
8. Harbottle H, Thakur S, Zhao S, White DG. Genetics of antimicrobial resistance. *Anim Biotechnol* 2006;17:111–124.
9. Berger S. Incidence of severe side effects during therapy with sulfonylurea and biguanides. *Horm Metab Res* 1985;17:111–115.
10. Barton D, Ollis WD. (1979). *Comprehensive Organic Chemistry*, vol 1–6. Oxford: Pergamon.
11. Chemler YY, Leonard E, Koffas MAG. Combinatorial mutasynthesis of flavonoid analogues from acrylic acids in microorganisms. *Org Lett* 2007;9:1855–1858.
12. Prakash O, Kumar R, Parkash V. Synthesis and antifungal activity of some new 3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl) chromones. *Eur J Med Chem* 2008;43:435–440.
13. Kuroda M, Uchida S, Watanabe K, Mimaki Y. Chromones from the tubers of *Eranthis cilicica* and their antioxidant activity. *Phytochemistry* 2009;70:288–293.
14. Larget R, Lockhart B, Renard P, Largeron M. A convenient extension of the Wessely-Moser rearrangement for the synthesis of substituted alkylaminoflavones as neuroprotective agents in vitro. *Bioorg Med Chem Lett* 2000;10:835–838.
15. Yu D, Chen CH, Brossi A, Lee KH. Anti-AIDS agents. 60. Substituted 3'R,4'R-di-O(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f] chromone (DCP) analogues as potent anti-HIV agents. *J Med Chem* 2004;47:4072–4082.
16. Valenti P, Bisi A, Rampa A, Belluti F, Gobbi S, Zampiron A et al. Synthesis and biological activity of some rigid analogues of flavone-8-acetic acid. *Bioorg Med Chem* 2000;8:239–246.
17. Horton DA, Bourne GT, Smythe ML. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. *Chem Rev* 2003;103:893–930.
18. Nowaskowska Z. A review of anti-infective and anti-inflammatory chalcones. *Eur J Med Chem* 2007;42:125–137.
19. Acharya BN, Saraswat D, Tiwari M, Shrivastava AK, Ghorpade R, Bapna S et al. Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines. *Eur J Med Chem* 2010;45:430–438.
20. Tanaka K, Toda F. Solvent-free organic synthesis. *Chem Rev* 2000;100:1025–1074.
21. Cave GW, Raston CL, Scott JL. Recent advances in solventless organic reactions: towards benign synthesis with remarkable versatility. *Chem Commun (Camb)* 2001;2159:2169.
22. Toda F. (2005). *Solid State Reaction topics in Current Organic Chemistry*. Berlin, Heidelberg, New York: Springer.
23. Wang GW. (2004). *Fullerene Mechanochemistry*. In: Nalwa HS, ed. *Encyclopedia of Nanoscience and Nanotechnology*, vol. 3. Stevenson Ranch: American Scientific Publishers, 557.
24. Nohara A, Umetani T, Sanno Y. A facile synthesis of 4-oxo-4H-1-benzopyran-3- carboxaldehydes by vilsmeier reagents. *Tetrahedron* 1974;30:3353–3561.
25. Singh SP, Sehgal S, Tarar LS, Dhawan SN. Synthesis of 2-[3-methyl or trifluoromethyl-5-(2-thienyl)-pyrazol-1-yl]thiazol and benzothiazoles. *Indian J Chem* 1990;29B:310–314.
26. Jursic BS, Neumann DM. Preparation of 5-formyl and 5-acetyl barbituric acids, including the corresponding Schiff bases and phenyl hydrazones. *Tetrahedron Lett* 2001;42: 8435–8439.
27. Cruickshank R, Duguid JP, Marmion BP, Swain RHA. (1975). *Medicinal Microbiology*. 12th edn, vol. II, London: Churchill Livingstone, 196–202.
28. Collins AH. (1976). In: *Microbiological Methods*, second edn. London: Butterworth.
29. Khan ZK. *In vitro* and *vivo* screening techniques for bioactivity screening and evaluation, *Proc Int Workshop UNIDO-CDRI* 1997:210–211.
30. Varma RS. (1998). *Antifungal Agents: Past, Present and Future prospects*. Lucknow, India: National Academy of Chemistry & Biology.
31. Wiley RH, Jarboe CH. *The Chemistry of Heterocyclic compounds*. Interscience, NY: 1967;22:183.